Abstract:Purpose In this study, we aimed to investigate the viability of utilizing CytoSorter (R) system to detect circulating tumor cells (CTCs) and to evaluate the diagnostic value of CTCs in breast cancer (BC). Methods A total of 366 females patients suspected of having BC and 30 healthy female volunteers were enrolled in this study. CTCs were enriched by CytoSorter (R), a microfluidic-based CTCs capturing platform. CTC detection was performed before operation or biopsy. Based on the biopsy results, patients were divided into two groups, namely patients with BC and patients with benign breast diseases (BBD). Patients with BBD and healthy volunteers were serving as controls. The correlation between CTC enumeration and patients' clinicopathological characteristics was evaluated. The receiver operating characteristic (ROC) curve was plotted to assess the diagnostic potency of CytoSorter (R) system in BC. Results Based on the biopsy results, 130 BC patients at different cancer stages and 236 patients with BBD were enrolled in the study. Seven subjects were dropped out from the study. CTCs were detected in 109 of 128 BC patients, in one of 29 healthy volunteers, and in 37 of 232 patients with BBD. Maximum CTC counts detected in BC patients, healthy volunteers, and patients with BBD were 8, 1, and 4, respectively. Statistical analysis showed CTCs could be used to distinguish BC patients from healthy volunteers and patients with BBD (P < .0001). Circulating tumor cells were statistically associated with patients' cancer stage (P = .0126), tumor size (tumor node metastasis [TNM] T stage, P = .0253), cancer type (invasive vs noninvasive, P = .0141), and lymph node metastasis (P = .0436). More CTCs were found in patients at advanced cancer stage or TNM T stage and in patients with invasive tumor or lymph node metastasis. Furthermore, CTC detection rates in BC patients at Tis and T1-4 stages were 50%, 81.67%, 91.07%, 100%, and 100%, respectively. When the CTC cut-off value was set to 2, the ROC curve gave an area under the curve (AUC) of 0.86 with a specificity and sensitivity of 95.4% and 76.56%, respectively. Taken together, CTCs could be used as a diagnostic aid in assistance of cancer screening and staging. Conclusion Circulating tumor cells were successfully isolated in BC patients using CytoSorter (R) system. CTCs can be used to differentiate BC patients from the patients with BBD or healthy volunteers, and as a diagnostic aid for early cancer diagnosis and cancer staging.

Establishment and Characterization of a Circulating Tumor Cell Line from a Breast Cancer Patient

Establishment and Characterization of a CTC Cell Line from Peripheral Blood of Breast Cancer Patient.

Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.

Evaluation of the Diagnostic Value of Circulating Tumor Cells with CytoSorter® CTC Capture System in Patients with Breast Cancer.

Isolation, culture & characterization ofthe circulating tumor cells from breast cancer patients' peripheral blood in vitro

Short-Term Ex Vivo Culture of CTCs from Advance Breast Cancer Patients: Clinical Implications

Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo

Characterization of Circulating Breast Cancer Cells with Tumorigenic and Metastatic Capacity

Self-Sterilizing and Regeneratable Microchip for the Precise Capture and Recovery of Viable Circulating Tumor Cells from Patients with Cancer.

Abstract 2239: Establishment of Lung Cancer CTCs Competent for Lung Metastasis

Establishment and Characterization of Two Novel Cholangiocarcinoma Cell Lines

Molecular Characterization of Circulating Tumor Cells-from Bench to Bedside

An Integrated Microfluidic Chip and Its Clinical Application for Circulating Tumor Cell Isolation and Single‐Cell Analysis

Circulating tumor cells and clinicopathologic characteristics of primary tumor of breast cancer patients:report of 128 cases

Clinical significance of circulating tumor cells in breast cancer patients

Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response

[Circulating Tumor Cells in Patients with Breast Tumors Were Detected by a Novel Device: a Multicenter, Clinical Trial in China].

Generally Applicable Circulating Tumor Cell Enrichment and Identification Through a Membrane Glycoprotein-Targeting Strategy Combining Magnetic Isolation and Biological Orthogonality Labeling.

Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application

Single-cell Analyses of Circulating Tumor Cells

Circulating Tumor Cells: Biological Features and Survival Mechanisms